Related Experiment Videos
Cyclandelate in the treatment of senile mental changes: a double-blind evaluation
Insights
Cyclandelate effectively treats geriatric patients with cerebrovascular insufficiency symptoms. This cerebral vasodilator is safe and may delay age-related cognitive deterioration with proper use.
Area of Science:
- Geriatric Medicine
- Pharmacology
- Neurology
Background:
- Cerebrovascular insufficiency is a growing concern in the elderly population.
- Cerebral vasodilators are being re-evaluated for therapeutic efficacy.
- Geriatric patients often present with complex symptoms requiring effective treatment.
Purpose of the Study:
- To assess the effectiveness of cyclandelate in treating symptoms of cerebrovascular insufficiency in geriatric patients.
- To evaluate cyclandelate's safety profile in an elderly population.
- To determine the optimal duration of cyclandelate therapy for geriatric patients.
Main Methods:
- A 12-week, double-blind, placebo-controlled study involving 58 geriatric patients.
- Patients received either 1,600 mg/day of cyclandelate or a placebo.
- Assessments included vital signs, adverse reactions, Sandoz Clinical Assessment-Geriatric (SCAG), Nurses Observation Scale for Inpatient Evaluation (NOSIE), and physician global assessment.
Main Results:
- Cyclandelate demonstrated safety and efficacy in treating specific symptoms of senility.
- Therapy duration of at least eight weeks is recommended for optimal results.
- Clinical evidence suggests cyclandelate may delay cognitive deterioration in selected patients.
Conclusions:
- Cyclandelate is a safe and effective treatment option for selected geriatric patients with symptoms of cerebrovascular insufficiency.
- Prolonged or appropriate duration of therapy is crucial for achieving benefits.
- The prudent use of cyclandelate may help mitigate age-related cognitive decline.
Abstract:
The treatment of cerebrovascular insufficiency and its many symptoms in the ever-increasing numbers of the aged, is of major concern to physicians engaged in such care. Despite past skepticism as to the degree of efficacy of cerebral vasodilators, there is renewed interest in this form of therapy. Our investigation was designed to assess the effectiveness of cyclandelate, under strict double-blind conditions, in 58 geriatric patients. The cyclandelate and placebo groups (32 and 26 patients respectively) received either 1,600 mg/day of cyclandelate in fractional doses, or identical-appearing placebo capsules--over a period of 12 weeks. During the initial examination and every four weeks thereafter, patients were assessed for possible changes in vital signs and for evidence of adverse reactions. In addition, the Sandoz Clinical Assessment-Geriatric (SCAG) and the Nurses Observation Scale for Inpatient Evaluation (NOSIE) were completed, with particular attention to symptom clusters. A final global assessment was made in which the physician rated patients according to their overall clinical condition. The results of our study and analysis indicate that cyclandelate is a safe and effective agent for treating certain symptoms of senility in properly selected patients, provided the therapy is carried on for at least eight weeks and, if indicated, for a longer period. Clinical evidence suggests that the prudent use of this drug may definitely delay deterioration.